Devoted Health Funding Hits $25 Billion Valuation in Series G Deal

From reported talks to a closed round

In late August, Business Insider reported that Devoted Health, a Medicare Advantage company, was negotiating a new round at a $25 billion valuation, citing people familiar with the matter.2 That valuation was well above the roughly $16 billion the company reached in a round earlier in 2026.2 Devoted would not discuss the talks, saying only that it does not comment on its capital raising activity.2

The deal has since closed. On October 1, Devoted announced close to $1.2 billion in new funding through a Series G led by Advent and co-led by Temasek, and coverage of the announcement put the company's valuation at $25 billion. The reported number held up. The jump from about $16 billion to $25 billion in under a year is one of the sharpest valuation increases in healthcare this year.

The headline amount needs a closer look. Of the roughly $1.18 billion package, $555 million is new primary capital in the Series G. The other $622 million is committed to a tender offer for existing shareholders, expected to close later in the fourth quarter.1 Other participants included The Space Between, GIC, Franklin Templeton, Generation, VZVC, Emerson Collective, Premji Invest and Andreessen Horowitz.1

Why the tender offer matters

Most headlines called this a $1.2 billion raise, and some deal trackers list the whole figure as Series G.84 The primary-versus-secondary split tells a different story. A little more than half the money goes to early investors and employees who want to sell some of their shares. Only the other half goes to the company to fund growth.1

That split is common for late-stage private companies that are putting off an IPO. Devoted was founded in 2017, and its earliest investors have now held their stakes for nearly a decade. The seed round was led by Venrock, and the Series A came in late 2017.10 A $622 million tender lets some of those holders sell without a public listing. It also tells new investors that the company feels no pressure to go public.

The primary capital is still large for a company that has raised money this often. In January, Devoted disclosed $366 million across two tranches: a $48 million Series F that closed in November 2025 and a $317 million Series F-Prime that closed in January 2026.61 Those two rounds plus the new $555 million add up to more than $900 million in primary equity in about a year.

The Orinoco pitch and the AI premium

Coverage of the August talks mostly explained the valuation in terms of artificial intelligence. Business Insider presented Devoted as the newest sign that pairing healthcare with AI earns a premium, and said investors are eager for companies that use AI to improve both patient care and the economics of medicine.2 Follow-up reports named Orinoco, the company's in-house AI platform, as the core of the investment case, along with fast growth in Medicare Advantage revenue paid for by the government.916

That framing fits current venture funding, where an AI label can raise a company's valuation multiple. Devoted's own history suggests a more grounded explanation. Earlier funding coverage described Orinoco as an end-to-end data analytics platform behind the company's health plans, provider partnerships and its in-house medical group, Devoted Medical.7 The company also built its own claims, care management and member service systems instead of licensing older insurer software.10

Orinoco is therefore not a recent AI add-on. It is the operating backbone of a company that is both an insurer and a care provider. Devoted earns most of its revenue from Medicare Advantage premiums paid by the federal government, and it provides care directly.2 Investors are paying for both halves of that structure, and AI is the newest way to describe it.

Our reading is that "AI-native insurer" is mostly a label for a valuation that rests on membership growth and vertical integration. The label helps sell the deal to growth-stage and sovereign investors. The underlying case is about operations.

Membership growth against a shrinking field

The numbers that best explain the valuation are about enrollment. Devoted had 466,000 members in January 2026, up 121% from a year earlier.2 Those members were spread across 29 states.16 By the Series G announcement, membership had passed 538,000, and the company said it plans to expand to 34 states.1

The rest of the market is moving the other way. UnitedHealthcare, the largest Medicare Advantage carrier, told investors early this year that it expected to lose about 1.1 million to 1.4 million members in 2026 as it gives up enrollment to restore margins.5 Other coverage says Humana, Molina and Providence have announced Medicare Advantage pullbacks or exits for 2027.12 One analysis found that only 39% of states had overall Medicare Advantage growth in 2026, and that overall program growth slowed to 3.2%, while Devoted grew by moving into counties that incumbents left.6

This is the part of the story most coverage agrees on. Devoted is growing while much of the industry retreats, and the gap between the two is driving the price. Large insurers are cutting back on medical costs and reimbursement pressure. Devoted is betting that its integrated model can price and manage that risk better. Investors at $25 billion are betting it is right.

There is a less flattering way to see the same facts. Picking up members in markets that incumbents found unprofitable can mean taking on the risks that pushed those incumbents out. Rapid growth in Medicare Advantage is only worth something if the medical costs of new members stay under control. One post-deal analysis noted that investors will increasingly watch retention, medical-cost management, quality ratings, margins and the economics of entering new markets.1

Where the reporting diverges

Reports on Devoted's finances do not always agree. The January round is one example. Some trackers list Centricus as the lead.4 Others say The Space Between led it in partnership with Centricus.106 Figures for total capital raised also differ. One profile cites about $2.6 billion before the Series G.10 Another tracker, counting the new round in full, puts lifetime funding at $3.82 billion.4

Growth figures vary too. Most outlets report the 121% membership increase.29 One funding database gives a 12% figure for the same period10, which looks like a transcription error given the consistent reporting elsewhere. The investor lists in the August coverage, which cited PitchBook and named Andreessen Horowitz, General Catalyst, Iconiq and Emerson Collective215, also differ from the October syndicate, which brings in Advent, Temasek and GIC.1

These gaps are normal for a private company that shares little. Readers should still treat any single number about Devoted's capital structure with some caution.

Valuation history in context

The $25 billion figure looks different against the company's history. Devoted reached about $12.7 billion after its 2021 Series D, which was led by SoftBank Vision Fund 2 and Uprising. Its valuation then barely changed for more than two years, with a December 2023 Series E at roughly $12.87 billion and an August 2024 extension at around $13 billion.10 At that time, revenue reported with the round was about $3.3 billion, a multiple of roughly four times revenue.10

So Devoted's valuation was essentially flat through the post-2021 correction and has nearly doubled since. The new money is not a frothy early bet. It comes after the company scaled its membership while its valuation stood still, and after the AI story gave late-stage investors a new way to justify the price.

What comes next

Compared with many AI funding stories in 2026, the risks here are concrete. Devoted's revenue depends on federal Medicare Advantage payments, and policy changes affect them directly. CMS expects the weighted average monthly Medicare Advantage premium to drop from $14.37 in 2026 to about $12 in 2027.1 That kind of pricing pressure makes it harder to compete on benefits alone.

The next year will test whether expanding to 34 states keeps the membership growth going without hurting medical cost ratios. It will also show whether the tender offer's completion in the fourth quarter signals wider secondary demand. And it will show whether Devoted's AI pitch holds up when the numbers investors watch are margins and star ratings. For now, investors are treating Devoted as the main Medicare Advantage growth story while incumbents shrink, and they have paid $25 billion to back that view.